Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. - Wikidata - wikimedia - TriplyDB

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

http://www.wikidata.org/entity/Q34736064

about

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer Analysis of different HER-2 mutations in breast cancer progression and drug resistance HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness.Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis.

P2860

Q26747729-5F3A30F3-1422-4A45-8E9F-866D6ED7D1BC Q26772969-AE52A47F-36AE-4269-886F-C4A39DD86C0D Q26797471-06EE0841-AF2C-4C93-AB7C-9AF7CF370460 Q35235832-31450BCB-626E-4117-AAC3-9F7D961AC533 Q35663687-96060B92-221B-4C9D-B5E3-5FFDAF9C9BC3 Q36064912-572A07B2-0F6D-437F-BB33-4A566CC2CD76 Q36107363-ADF9F5CF-4E5C-4C61-A547-ED60A927DEB7 Q36210992-46371C6D-4068-4D16-B33F-5AD62EA7BC04 Q36545717-2AFA8A90-BBCB-4EC9-BDC4-F8E0EA7F5586 Q37636623-48DAFE4A-CB26-4A36-B066-B9BA9B0A1248 Q37708733-05721427-3CAA-4144-AC24-DE7D1D7CBA97 Q38661390-C1767B8B-3E7E-4C9D-B25D-4B63204E7D5F Q38890318-CF4C9417-B782-4D5A-A7AE-56EE25222DBF Q47130450-6895AC89-3FD1-4CF8-BFB8-02AC1AAC3CC5

P2860

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

http://www.wikidata.org/entity/Q34736064

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

@ast

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

@en

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

@nl

type

label

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

@ast

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

@en

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

@nl

prefLabel

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

@ast

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

@en

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

@nl

P1433

Q34736064-F69DD437-2617-4CAF-BBD1-009B6CED6420

P1476

Q34736064-8091E7D8-245A-4F5B-A6FE-40F799FEC95E

P2093

Q34736064-57213806-4B74-4852-89EC-EB53776C89AE

Q34736064-791B2FBB-EEBF-41DF-B71D-B46594A0212A

Q34736064-7D046136-8391-4A9F-A42F-777D32F22844

Q34736064-85569F4B-A779-41F2-8404-1049B55247DA

Q34736064-B4307C4B-2350-4C80-9B54-FB9E73B46EC4

Q34736064-BC738D25-7C25-4E25-8D56-2963AAE8EF55

Q34736064-CACF139B-A585-45AD-9C8A-1346D5342321

Q34736064-D0D05E87-C181-4F97-B008-3A0F3EAB0C3E

P2860

Q34736064-384DD067-76F1-45B6-B566-ED2413303AB2

Q34736064-3BE73931-E7AE-4CC1-981E-00EF1709E16A

Q34736064-424B0E54-99E4-4678-9563-08621C944799

Q34736064-49C812DA-BC58-4EB1-8099-54D8DA933548

Q34736064-4D5D54AE-C14E-4FB4-959B-B0ADB6AC010D

Q34736064-631835A2-210E-4717-A9C9-C4601602D1FE

Q34736064-744761F1-658E-48F9-B3C7-C4CA58147059

Q34736064-9094FBDD-4453-4CB3-9B05-14B10D4093D3

Q34736064-91AC1270-F04A-43EC-B0C0-1AC798AF84D8

Q34736064-98EEADC3-4E39-4CA2-810D-21D068BCE7A8

P31

Q34736064-B8DF7AAB-0D10-4B3B-BE3E-6E89A18CFE52

P356

Q34736064-70BD030A-8488-4DBB-B21C-D2D7D69EC8DD

P407

Q34736064-5D6CB300-AAB0-4BC2-962F-01D4E5C1F156

P433

Q34736064-C35166D1-46C5-4B2F-A821-8A837815EF4A

P478

Q34736064-A6F4F5E2-C64D-419B-8CD2-4A72E534E838

P50

Q34736064-28A08714-1510-4CC5-9F0F-C397E904135D

Q34736064-429D584B-F801-4AC0-B6E7-A5E024D06DBA

Q34736064-535F4AFB-DE54-4250-87EC-83DCC674B62F

Q34736064-69BE9978-9B76-48BC-AC83-473311D1BB92

Q34736064-7CB8FD6A-3CDC-4A1B-BFD1-EDF1F8A65A27

Q34736064-AFB97DFB-8DF3-406F-8644-FEEB5E3C3989

Q34736064-C2A831A0-3F93-46BF-A6B8-FD3A8D353EE0

Q34736064-C63E685B-A009-4369-AD77-8BAECA571975

Q34736064-CDBDDE5B-4365-44DE-A69E-F11E00C224F1

P577

Q34736064-02564718-16B3-4C8A-953D-38190CC065AB

P698

Q34736064-764ACEBF-16C1-43D9-9004-8DE361346405

P921

Q34736064-FC4147F4-6D12-4BBF-8836-ABCE7CA1456F

P932

Q34736064-D8B46075-9817-49CF-A89F-E65EB4595FE2

P356

P1433

Journal of the National Cancer Institute

P1476

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy

@en

P2093

Atanasio Pandiella

http://www.w3.org/2001/XMLSchema#string

Isabel T Rubio

http://www.w3.org/2001/XMLSchema#string

Josep Lluís Parra-Palau

http://www.w3.org/2001/XMLSchema#string

José Baselga

http://www.w3.org/2001/XMLSchema#string

Kim Pedersen

http://www.w3.org/2001/XMLSchema#string

Marta Escorihuela

http://www.w3.org/2001/XMLSchema#string

Maurizio Scaltriti

http://www.w3.org/2001/XMLSchema#string

Rocio Vicario

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Supervised risk predictor of breast cancer based on intrinsic subtypes

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.

p95HER2 and breast cancer.

A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.

Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

P31

scholarly article

P356

10.1093/JNCI/DJU291

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Charles M. Perou

Beatriz Morancho

Mariano F Zacarias Fluck

Joaquin Arribas

P577

2014-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25253614

http://www.w3.org/2001/XMLSchema#string

P921

P932

4271027

http://www.w3.org/2001/XMLSchema#string